研究报告 Research Report 24 Aug 2025 金斯瑞生物科技 Genscript Biotech (1548 HK) 2025 年半年报点评：各板块稳健增长，看好下半年趋势加速 2025H1Review: steady growth for all sectors, optimistic about the accelerated trend of 2H25 [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$18.52 目标价 HK$24.62 HTI ESG 5.0-3.8-4.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$40.39bn / US$5.17bn 日交易额 (3 个月均值) US$59.91mn 发行股票数目 2,181mn 自由流通股 (%) 51% 1 年股价最高最低值 HK$18.56-HK$8.97 注：现价 HK$18.5 ...

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of HKD 29.90 [1][5][32] Core Views - The company reported a revenue of HKD 27.4 billion for the first half of 2025, a decrease of 6.5% year-on-year, while the net profit attributable to shareholders was HKD 7.709 billion, an increase of 27.5% year-on-year. However, the recurring profit was below expectations at HKD 3.391 billion, down 15.7% year-on-year [1][5] - The property development segment is experiencing a harvest period, with profits from property development reaching HKD 5.542 billion, up 218.5% year-on-year, driven by the recovery of the Hong Kong property market [1][4] - The report highlights the challenges faced by the Hong Kong rail operations due to rising operational costs, with EBIT down 76% year-on-year despite a revenue increase of 3.3% [2][3] Summary by Sections Financial Performance - The company’s revenue for 1H25 was HKD 27.4 billion, a decrease of 6.5% year-on-year, while net profit attributable to shareholders was HKD 7.709 billion, an increase of 27.5% year-on-year. The recurring profit was HKD 3.391 billion, which was 9% lower than expectations [1][5] - The company plans to distribute an interim dividend of HKD 0.42 per share, unchanged from the previous year [1] Operational Insights - The Hong Kong rail operations generated revenue of HKD 11.5 billion in 1H25, up 3.3% year-on-year, but EBIT fell to HKD 0.98 billion, down 76% year-on-year due to increased employee costs and inflation [2] - The report notes that the new rental rates for shops in the Hong Kong stations continued to decline, with a drop of 7.0% year-on-year [3] Property Development - The property development segment recorded a net profit of HKD 5.542 billion, primarily from projects in the Whampoa area, with a significant increase attributed to a low base from the previous year [4] - The report indicates that the Hong Kong property market is showing signs of recovery, with a 0.6% increase in the private residential price index over three consecutive months [4] Profit Forecast and Valuation - The report adjusts the net profit forecasts for 2025-2027 downwards by 11%, 3%, and 17% to HKD 18.1 billion, HKD 21 billion, and HKD 11 billion respectively [5][31] - The valuation is based on a discounted cash flow (DCF) method with a WACC of 7.0% and a perpetual growth rate of 3%, leading to a target price of HKD 29.90 per share [5][32]

Investment Rating - The report maintains an "Accumulate" rating for the company [7][24]. Core Views - The company reported a total revenue of 49.34 billion yuan for the first half of 2025, a year-on-year increase of 1.44%, while the net profit attributable to the parent company was 2.077 billion yuan, up 3.01% year-on-year. However, the second quarter saw a decline in revenue and net profit, with a year-on-year decrease of 2.6% and 8.25%, respectively, primarily due to weak performance in the central air conditioning segment and increased asset impairment [1][2][3]. Summary by Sections Financial Performance - In the first half of 2025, the company's central air conditioning business faced pressure, with revenue from the subsidiary Hisense Hitachi declining by 6% year-on-year to 10.66 billion yuan, and net profit down by 4.9% to 1.86 billion yuan. Domestic sales of central air conditioning dropped by 15.9%, while external sales showed a growth of 24.9% [2][3]. - The home air conditioning segment performed positively, with a revenue increase of approximately 14% year-on-year. The company’s ice washing business also saw a modest revenue growth of 4.8% [3][4]. Profitability and Margins - The gross margin for the first half of 2025 was reported at 21.48%, an increase of 0.69 percentage points year-on-year, driven by improved overseas margins and rising margins in the ice washing segment [4][5]. - The report indicates a slight increase in expense ratios due to sports marketing and foreign exchange fluctuations, with the expense ratio rising by 0.51 percentage points year-on-year [4]. Future Outlook - The company forecasts net profits attributable to the parent company of 3.75 billion yuan, 4.20 billion yuan, and 4.70 billion yuan for 2025, 2026, and 2027, respectively. The report suggests that the company will benefit from the release of replacement demand and its strong brand presence [5][21]. - The target market capitalization is set at 490.98 billion yuan, with a target price of 35.42 yuan for A-shares and 30.62 HKD for H-shares, reflecting a valuation discount due to exchange rate and market volatility risks [5][24].

Core Viewpoint - The company reported a slight year-on-year increase in total power generation of 0.3% for the first four months of the year, with significant growth in wind and solar power generation, while thermal power generation declined due to asset sales [1][2] Group 1: Power Generation Performance - Total power generation for the company in January to April remained stable, with a year-on-year increase of 0.3% [1] - Wind and solar power generation saw substantial increases of 32.1% and 13.6% respectively [1] - Thermal power generation decreased by 14.2% due to the sale of equity at the end of last year [1] - Hydropower generation experienced a significant drop in April, with a year-on-year decline of 53.3% and a month-on-month decline of 26.5% due to fluctuations in water inflow [1] Group 2: Fuel Costs and Profitability - The price of thermal coal weakened in the second quarter, leading to an expected improvement in the price differential for thermal power generation in the first half of the year [1] - The company anticipates a 2% higher price differential for thermal power generation than previously expected due to a more than 7% drop in domestic thermal coal prices since the end of March [1] - The fuel cost forecast for the thermal power segment has been reduced by 1% to RMB 0.249 per kilowatt-hour, reflecting an approximate 8% year-on-year decrease [1] Group 3: Financial Adjustments and Valuation - The company has adjusted its 2025 water power utilization hours down by about 1% to reflect weaker generation in April [2] - Following adjustments to the financial model, the profit forecasts for 2025 and 2026 have been increased by 1.0% and 1.4% respectively [2] - The valuation standard for the water power segment has been raised to 1.9 times the 2025 book value, up from 1.5 times, based on the asset injection valuation [2] - The target price for the company has been revised upward to HKD 3.77 from HKD 3.51 based on a segmented valuation approach [2] Group 4: Shareholder Confidence and Dividends - The parent company has increased its stake in the company, indicating confidence in its development, with a total increase of 1% over the past 12 months [2] - The current dividend yield of 6% for 2025 and 7% for 2026 remains attractive to investors despite market fluctuations [2] - The company maintains a "buy" rating based on these factors [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 10.75 CNY per share [1][5]. Core Views - The company's aramid business is experiencing steady growth, while the spandex segment is under pressure due to ongoing supply-demand imbalances and price competition [4][10]. - The forecast for the company's net profit for 2025-2027 has been adjusted to 222 million, 292 million, and 361 million CNY respectively, reflecting a significant downward revision from previous estimates [5][10]. - The company is expected to maintain a strong position in the aramid market, which has a projected compound annual growth rate of 5-10% globally, despite current price competition [10]. Financial Summary - The company reported a revenue of 3,925 million CNY in 2023, with a slight increase to 3,929 million CNY in 2024, and projected revenues of 4,494 million CNY in 2025, 4,938 million CNY in 2026, and 5,359 million CNY in 2027, indicating a growth trajectory [7][13]. - The net profit attributable to the parent company is forecasted to decline significantly in 2024 to 90 million CNY, before rebounding to 222 million CNY in 2025, reflecting a growth of 147.9% [7][10]. - The gross margin is expected to improve from 16.0% in 2024 to 21.4% by 2027, indicating a recovery in profitability [7][10]. Segment Performance - The spandex segment is projected to face continued challenges, with a forecasted gross margin of -11.86% in 2024, while the aramid segment is expected to see a 13% increase in sales volume [10]. - The company is advancing its aramid-coated diaphragm industrialization process, with pilot projects already in production and full-scale production expected to begin in 2025 [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 10.75 CNY per share [1][5]. Core Views - The report highlights that the aramid business is steadily growing, while the spandex segment is under pressure due to ongoing supply-demand imbalances and price competition [4][9]. - The company has adjusted its profit forecasts for 2025-2027, with expected net profits of 222 million, 292 million, and 361 million CNY respectively, reflecting a significant downward revision from previous estimates [5][9]. Financial Performance Summary - The company reported a revenue of 3,925 million CNY in 2023, with a slight increase to 3,929 million CNY in 2024, and projected revenues of 4,494 million CNY in 2025, 4,938 million CNY in 2026, and 5,359 million CNY in 2027, indicating a growth rate of 14.4% in 2025 [7][12]. - The net profit attributable to the parent company is expected to recover from 90 million CNY in 2024 to 222 million CNY in 2025, showing a year-on-year growth of 147.9% [5][12]. - The gross margin is projected to improve from 16.0% in 2024 to 21.4% in 2027, while the net margin is expected to rise from 2.3% in 2024 to 6.7% in 2027 [7][12]. Segment Analysis - The spandex segment is facing challenges with a projected gross margin of -11.86% in 2024, leading to further losses [9]. - The aramid segment is expected to maintain a growth trajectory, with a 13% increase in sales volume in 2024 despite a decline in revenue and gross profit due to intensified price competition [9]. - The company is advancing its aramid-coated diaphragm industrialization process, with pilot projects already in production and full-scale production expected to commence in 2025 [9].

Investment Rating - The report maintains a "Buy" rating for the company [7][8] Core Views - The company reported a significant revenue growth of 20.96% year-over-year (yoy) in 1Q25, reaching 9.655 billion RMB, with a net profit increase of 89.06% yoy to 3.672 billion RMB [1] - The company expects a revenue growth acceleration in 2025-2026, driven by a strong order backlog and the performance of its TIDES business [1][2] - The TIDES segment showed remarkable growth, with a revenue increase of 187.6% yoy in 1Q25, contributing to the overall positive outlook for the company's performance [3] Summary by Sections Financial Performance - In 1Q25, the company achieved a revenue of 9.655 billion RMB, with a net profit of 3.672 billion RMB, and an adjusted non-IFRS net profit of 2.68 billion RMB, reflecting a 40.0% yoy increase [1] - The company’s order backlog reached 52.33 billion RMB in 1Q25, representing a 47.1% yoy increase [2] Business Segments - WuXi Chemistry's revenue in 1Q25 was 7.39 billion RMB, up 32.9% yoy, with a non-IFRS gross margin of 47.5% [3] - The TIDES business saw a significant increase in orders, with a backlog growth of 105.5% yoy in 1Q25 [3] Profitability and Valuation - The report forecasts net profits of 11.794 billion RMB for 2025, with a projected growth of 24.80% yoy [5] - The company’s valuation is based on a sum-of-the-parts (SOTP) approach, estimating a fair value of 269.44 billion RMB for A-shares and 278.28 billion HKD for H-shares [12]